RBC Capital Maintains Outperform on Acadia Pharmaceuticals, Lowers Price Target to $36
RBC Capital analyst Brian Abrahams maintains Acadia Pharmaceuticals (NASDAQ:ACAD) with a Outperform and lowers the price target from $37 to $36.
Stocks · News reference
UBS Downgrades Acadia Pharmaceuticals to Neutral, Lowers Price Target to $23
UBS analyst Ashwani Verma downgrades Acadia Pharmaceuticals (NASDAQ:ACAD) from Buy to Neutral and lowers the price target from $49 to $23.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Acadia Pharmaceuticals Announces USPTO Issued Notice Of Allowance For U.S. Patent Application No. 17/590,496, Titled “Methods and Compositions for Treatment of Rett Syndrome.”
https://acadia.com/en-us/media/news-releases/acadia-pharmaceuticals-announces-allowance-of-u-s--patent-covering-weight-banded-dosing-of-trofinetide-extending-u-s--patent-protections-to-march-2041
ACADIA Pharmaceuticals shares are trading lower after multiple analyst firms lowered their respective price targets on the stock.